Reuters -- France’s Sanofi-Aventis has not yet received a letter from the U.S. health regulator giving the go-ahead for the sale of heart drug Multaq, but expects a decision during the second quarter, it said on Monday.
Reuters -- France’s Sanofi-Aventis has not yet received a letter from the U.S. health regulator giving the go-ahead for the sale of heart drug Multaq, but expects a decision during the second quarter, it said on Monday.
